Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review

被引：3

作者：

Yoshimatsu, Yuki ^{[1
,2
]}

Ebi, Noriyuki ^{[1
]}

Ooi, Ryunosuke ^{[1
]}

Sueyasu, Takuto ^{[1
]}

Nishizawa, Saori ^{[1
]}

Munechika, Miyuki ^{[1
]}

Yoshimine, Kohei ^{[1
]}

Ko, Yuki ^{[1
]}

Ide, Hiromi ^{[1
]}

Tsuruno, Kosuke ^{[1
]}

Tobino, Kazunori ^{[1
,3
]}

机构：

[1] Iizuka Hosp, Dept Resp Med, Iizuka, Fukuoka, Japan

[2] Hyogo Coll Med, Dept Physiol, Nishinomiya, Hyogo, Japan

[3] Juntendo Univ, Dept Resp Med, Grad Sch Med, Tokyo, Japan

来源：

INTERNAL MEDICINE | 2021年 / 60卷 / 07期

关键词：

epidermal growth factor receptor; EGFR; tyrosine kinase inhibitor; TKI; adenosquamous; rechallenge; TYROSINE KINASE INHIBITORS; CANCER PATIENTS; POOLED ANALYSIS; EGFR; GEFITINIB; EFFICACY; THERAPY; NSCLC;

D O I：

10.2169/internalmedicine.5463-20

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib was resumed after sixth-line chemotherapy was ineffective, showing efficacy again. Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. This is the first report to show its effect in a case of rechallenge after intervening chemotherapy. It may therefore be important to evaluate EGFR in never-smoker lung squamous cell carcinoma patients.

引用

页码：1067 / 1071

页数：5

共 18 条

[1] The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV [J].

Akamatsu, Hiroaki ;

Ninomiya, Kiichiro ;

Kenmotsu, Hirotsugu ;

Morise, Masahiro ;

Daga, Haruko ;

Goto, Yasushi ;

Kozuki, Toshiyuki ;

Miura, Satoru ;

Sasaki, Takaaki ;

Tamiya, Akihiro ;

Teraoka, Shunsuke ;

Tsubata, Yukari ;

Yoshioka, Hiroshige ;

Hattori, Yoshihiro ;

Imamura, Chiyo K. ;

Katsuya, Yuki ;

Matsui, Reiko ;

Minegishi, Yuji ;

Mizugaki, Hidenori ;

Nosaki, Kaname ;

Okuma, Yusuke ;

Sakamoto, Setsuko ;

Sone, Takashi ;

Tanaka, Kentaro ;

Umemura, Shigeki ;

Yamanaka, Takeharu ;

Amano, Shinsuke ;

Hasegawa, Kazuo ;

Morita, Satoshi ;

Nakajima, Kazuko ;

Maemondo, Makoto ;

Seto, Takashi ;

Yamamoto, Nobuyuki .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (07) :731-770

[2] Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer [J].

Cappuzzo, Federico ;

Morabito, Alessandro ;

Normanno, Nicola ;

Bidoli, Paolo ;

Del Conte, Alessandro ;

Giannetta, Laura ;

Montanino, Agnese ;

Mazzoni, Francesca ;

Buosi, Roberta ;

Burgio, Marco Angelo ;

Cerea, Giulio ;

Chiari, Rita ;

Cortinovis, Diego ;

Finocchiaro, Giovanna ;

Foltran, Luisa ;

Migliorino, Maria Rita ;

Tiseo, Marcello ;

Ferrari, Silvia ;

De Marinis, Filippo .

LUNG CANCER, 2016, 99 :31-37

[3] Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach [J].

Cortiula, Francesco ;

De Maglio, Giovanna ;

Cangi, Maria Giulia ;

Gerratana, Lorenzo ;

Lisanti, Camilla ;

Bonura, Salvatore ;

Fasola, Gianpiero ;

Follador, Alessandro .

ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (01)

[4] Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) [J].

Dearden, S. ;

Stevens, J. ;

Wu, Y. -L. ;

Blowers, D. .

ANNALS OF ONCOLOGY, 2013, 24 (09) :2371-2376

[5] How Sensitive Are Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene-Sensitive Mutations? [J].

Hata, Akito ;

Katakami, Nobuyuki ;

Yoshioka, Hiroshige ;

Kunimasa, Kei ;

Fujita, Shiro ;

Kaji, Reiko ;

Notohara, Kenji ;

Imai, Yukihiro ;

Tachikawa, Ryo ;

Tomii, Keisuke ;

Korogi, Yohei ;

Iwasaku, Masahiro ;

Nishiyama, Akihiro ;

Ishida, Tadashi .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) :89-95

[6] Clinical and genetic features of lung squamous cell cancer in never-smokers [J].

Huang, Yangle ;

Wang, Rui ;

Pan, Yunjian ;

Zhang, Yang ;

Li, Hang ;

Cheng, Chao ;

Zheng, Difan ;

Zheng, Shanbo ;

Li, Yuan ;

Shen, Xuxia ;

Hu, Haichuan ;

Cai, Deng ;

Wang, Shengfei ;

Zhang, Yawei ;

Xiang, Jiaqing ;

Sun, Yihua ;

Zhang, Jie ;

Chen, Haiquan .

ONCOTARGET, 2016, 7 (24) :35979-35988

[7] Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database [J].

Kobayashi, Keigo ;

Soejima, Kenzo ;

Fukunaga, Koichi ;

Shintani, Yasushi ;

Sekine, Ikuo ;

Shukuya, Takehito ;

Takayama, Koichi ;

Inoue, Akira ;

Okamoto, Isamu ;

Kiura, Katsuyuki ;

Takahashi, Kazuhisa ;

Yamamoto, Nobuyuki ;

Takiguchi, Yuichi ;

Miyaoka, Etsuo ;

Okumura, Meinoshin ;

Yoshino, Ichiro .

LUNG CANCER, 2020, 146 :236-243

[8] Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors [J].

Landi, Lorenza ;

Tiseo, Marcello ;

Chiari, Rita ;

Ricciardi, Serena ;

Rossi, Elisa ;

Galetta, Domenico ;

Novello, Silvia ;

Milella, Michele ;

D'Incecco, Armida ;

Minuti, Gabriele ;

Tibaldi, Carmelo ;

Salvini, Jessica ;

Facchinetti, Francesco ;

Haspinger, Eva Regina ;

Cortinovis, Diego ;

Santo, Antonio ;

Banna, Giuseppe ;

Catino, Annamaria ;

GiajLevra, Matteo ;

Crino, Lucio ;

de Marinis, Filippo ;

Cappuzzo, Federico .

CLINICAL LUNG CANCER, 2014, 15 (06) :411-417

[9] Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient [J].

Metro, Giulio ;

Baglivo, Sara ;

Siggillino, Annamaria ;

Ludovini, Vienna ;

Chiari, Rita ;

Rebonato, Alberto ;

Bellezza, Guido .

CLINICAL DRUG INVESTIGATION, 2018, 38 (10) :983-987

[10] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

← 1 2 →